Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Sudha Seshadri¹  Daniel Levy¹  Alexa S. Beiser¹  Sarah R. Preis¹  Paul Courchesne¹  Vincent Chouraki¹  Galit Weinstein¹ 

[1] Framingham Heart StudyFraminghamMAUSA;

关键词: Epidemiology;    Plasma clusterin;    Dementia;    Alzheimer's disease;    Stroke;    Risk factors;   

DOI  :  10.1016/j.dadm.2016.06.005

来源: DOAJ

【 摘 要 】

Abstract Introduction Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke. Methods Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox‐proportional hazards models and examined potential interactions. Results A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64–23.89; P = .007) and with decreased risk of dementia (HR = 0.53, 0.32–0.88; P = .013) and stroke (HR = 0.78, 0.63–0.97; P = .029) among younger participants. Discussion The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age‐related factor.

【 授权许可】

Unknown